Medy-Tox Inc.
Research Medy-Tox Inc. (086900.KQ) on Bullrun: market cap KRW 438.52B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker086900.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 438.52B
- Financial periodQ2 2026
- RevenueKRW 68.70B
- Net incomeKRW 3.11B
- Free cash flowKRW 3.30B
- Gross margin59.8%
Valuation Snapshot
latest market cap is KRW 438.52B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 438.52B | n/a | 1.8% | 1200 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1200 KRW.
About Medy-Tox Inc.
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medy-Tox Inc.'s market cap?
Medy-Tox Inc.'s market capitalization is KRW 438.52B.
What does Medy-Tox Inc. do?
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles.